The rise of a public health manager expert : John Adlesich about healthcare industry trends: Deeper relationships and back-up suppliers. The value of vendor-of-choice relationships became apparent as many hospitals scrambled for pandemic-related supplies. The key is striking a strategic balance between price, performance and trust. Getting the lowest price but lacking a relationship that cannot be “prioritized” in a crisis is not ideal. Neither is overreliance on one vendor without having plans B, C and D in place. We see many organizations developing connections with tiers of back-up suppliers — often smaller and geographically closer than their primary vendors — to gain flexibility, speed and as much certainty as possible that critical items will be on hand when needed.
John Adlesich about behavior therapy in 2021: ESDM uses behavioral principals to encourage developmental growth in language, cognition, social skills, and the achievement of other developmental milestones. While intensive, ESDM is meant to be enjoyable and can be implemented with very young children and infants. Emphasis is placed on capturing and holding attention through providing enjoyable and meaningful activities. AutismSpeaks.org indicates that ESDM therapy: Is designed to be enjoyable for the child and resembles play more than therapy (though it is therapeutic) Should be developed by trained professionals but can be utilized by all family members as well as other caregivers Can be more even more effective if begun in infancy or early childhood Focuses on capturing and maintaining attention with activities that teach social behaviors, communication, and other socially significant behaviors Choosing the Right Therapies for You and Your Child.
John Adlesich about healthcare industry trends: Democratic control in the Senate will also impact healthcare. For example, Washington state Senator Patty Murray will chair the Senate Committee on Health, Education, Labor, and Pensions. She has advocated for a more robust federal response on COVID-19. And Senator Ron Wyden, Oregon, leads the Finance Committee and has pushed for drug pricing reform and drug price negotiation. These appointments and nominations point to a strong emphasis on COVID-19 recovery and vaccine distribution and coordination. For example, Fauci remains as the Director of the National Institute of Allergies and Infectious Diseases, and there’s now a COVID-19 data director (Shahpar), indicating this administration will emphasize data and reporting. Also evident in these appointments is a Biden administration focus on health equity and healthcare disparities—particularly with Nunez-Smith as the first Equity Task Force Chair for COVID-19. John Adlesich currently works as administrator at Marquis Companies. His latest healthcare industry experience includes positions as executive director at Powerback Rehabilitation Lafayette (Genesis Healthcare) between Aug 2020 – Jan 2021, administrator at Mesa Vista of Boulder between Mar 2019 – Aug 2020, chief executive officer at Sedgwick County Memorial Hospital between Jul 2018 – Feb 2019, interim chief operating officer at Toiyabe Indian Health Project between Mar 2018 – Jun 2018.
John Adlesich believes that 2021 is an important year for the healthcare industry. There will be particular momentum for programs that have bipartisan support, including payment policies that move away from fee-for-service reimbursement and toward models that drive lower-cost and higher-quality outcomes. The overall movement to value will get a shot in the arm from two principal forces in 2021: 1) the Biden Administration’s commitment to build on the ACA’s legacy by doubling down on alternative payment models and mandatory payment changes and 2) the pandemic. When it comes to policy, the new Administration will not need convincing that value-based care improves quality and reduces costs. Ample research shows that since the move to value began, overall health spending as a percent of GDP has slowed, cutting more than $600 billion out of the budget trajectory that was predicted in 2010. Because these programs are net savers, expanding their reach will be an important and immediate objective that could be used to offset some of the COVID-19 relief spending. To that end, we are likely to see Biden’s HHS make fee-for-service less attractive and push at least some mandatory alternative payment models. In addition, the Administration is also likely to move beyond endless testing of models, making proven programs permanent, creating added incentives to enable scale, and leading the way for private payers to follow suit with value-based programs of their own.